Relatlimab-Nivolumab Combo Deemed Promising in Resectable Melanoma
Source: Cancer Therapy Advisor, October 2022
Combination relatlimab and nivolumab yields a high pathologic complete response (pCR) rate in patients with resectable stage III or oligometastatic stage IV melanoma, according to a study published in Nature.
The phase 2 study (ClinicalTrials.gov Identifier: NCT02519322) enrolled 30 patients with resectable melanoma.
A total of 29 patients received 2 neoadjuvant doses of nivolumab (480?mg) and relatlimab (160?mg) intravenously every 4 weeks, which was followed by surgery. Patients then received 10 doses of adjuvant combination therapy.